Deals review
- Deals review
- Deal details
Orexo completes the acquisition of Biolipox, appoints new CEO and publishes a prospectus
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Related deals
Orexo to acquire Biolipox - building a specialty pharma company driven by innovation
Orexo acquires a UK drug delivery company
NicOx and Biolipox Enter into Collaboration
Biolipox Signs Asset Purchase Agreement with Inflazyme Pharmaceuticals
Biolipox – Inflazyme Pharmaceuticals Transaction Completed
Gedeon Richter announces agreement with the Swedish company Orexo for Orexo's pain product Rapinyl™
Related categories
- Therapeutic target
- Central Nervous System
- Industry sector
- Biotechnology
- Pharmaceutical
More deals
Latest deals
- Biovator and BASF sign technology development agreement
- Agfa HealthCare signs four-year agreement with Chinese partners for distribution of radiography solutions, potentially worth 500 million US dollar
- Omnicare Announces Acquisition of Continuing Care Rx
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program
Most viewed deals
- Recommended acquisition of Acambis plc ("Acambis") by Sanofi Pasteur Holding ("Sanofi Pasteur") by way of scheme of arrangement Posting of Scheme Document
- Omnicare Announces Acquisition of Continuing Care Rx
- Bayer CropScience and Janssen PMP conclude research agreement:
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- Biovator and BASF sign technology development agreement
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us